Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Coral Pharmaceuticals LTD
WARNING LETTER
•Coral Pharmaceuticals LTD•May 24, 2019

Coral Pharmaceuticals LTD – FDA Warning Letter, May 24, 2019

Record Details

On October 9, 2019, the FDA issued a Warning Letter to Coral Pharmaceuticals Ltd. following an inspection from May 20-24, 2019, at their Freeport City, Grand Bahama facility. The inspection revealed significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated. The firm's June 6, 2019, response to the FDA Form 483 was deemed inadequate.

Key violations include: 1. **Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))**: The firm manufactured a homeopathic drug product derived from a toxic ingredient without adequate process validation data. The manufactured product's concentration was approximately (b)(4) mcg/mL, equivalent to a (b)(4)X homeopathic dilution, but labeled as (b)(4)X, meaning the active concentration was (b)(4) orders of magnitude higher than labeled. 2. **Failure to conduct identity testing for components and validate supplier analyses (21 CFR 211.84(d)(1) and (2))**: The firm did not perform identity testing on a toxic component before use and relied on supplier Certificates of Analysis (COA) without establishing their reliability. 3. **Failure to establish an adequate quality control unit (211.22

Company
Coral Pharmaceuticals LTD
Inspection date
May 24, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · be324400-2453-4732-b2e9-b6756cf4c5d7

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.100(a)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 CFR 211.22(a)

Full citation text and observation details available on the Dashboard.

Other documents for Coral Pharmaceuticals LTD
  • 483 - 2019-05-24May 24, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Coral Pharmaceuticals LTD
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.